MedTrace Logo

Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

NCT01003808 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2013-04-17

No results posted yet for this study

Summary

The purpose of this study is to determine the biological recommended dose of IMF-001.

Conditions

  • Esophageal Cancer

Interventions

BIOLOGICAL

IMF-001

100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).

Sponsors & Collaborators

  • ImmunoFrontier, Inc.

    lead INDUSTRY

Principal Investigators

  • Daiju Ichimaru, BSc · ImmunoFrontier, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-03-31
Completion
2012-12-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01003808 on ClinicalTrials.gov